📋 Browse Articles

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
Filtered by: EXT1 ✕ clear all
🏷️ Tags (31979 usages)
📦 Other 1510
▸ Other (850)
brain-derived neurotrophic factor (39)neuroplasticity (32)exercise (20)neurobiology (19)neurotoxicity (18)trkb (16)traditional chinese medicine (15)genetics (15)neurotrophic factors (14)hippocampal (13)central nervous system (12)neuroprotective (11)gut-brain axis (10)neurology (10)stroke (10)obesity (9)neurotrophic (9)psychology (9)dementia (9)zebrafish (8)bipolar disorder (8)neurotrophins (8)blood-brain barrier (8)aging (7)anti-inflammatory (7)neuropsychiatric disorders (7)memory (7)nanoparticles (7)neuropathic pain (7)neurotransmission (6)neurological disorders (6)mental health (6)neurotrophin (6)rats (6)stem cells (6)neuromodulation (6)astrocytes (6)neurodevelopmental disorders (6)psychiatry (6)cns (5)neuronal cells (5)meta-analysis (5)bioavailability (5)biochemistry (5)pathology (5)psychedelics (5)probiotics (5)amyloid-β (5)epilepsy (5)neurodevelopment (5)polymorphism (5)akt (5)aerobic exercise (5)astrocyte (4)nutrition (4)metabolomics (4)toxicity (4)neuroimmune (4)amyloid beta (4)myokines (4)brain health (4)rat model (4)physical exercise (4)neurotransmitter (4)ischemic stroke (4)neuropathology (4)physical activity (4)ngf (4)mesenchymal stem cells (4)neurodevelopmental disorder (4)physiological (3)overactive bladder (3)neuroblastoma (3)amyloid-beta (3)pathophysiology (3)extracellular vesicles (3)immune cells (3)microbiota (3)pi3k (3)neurotransmitters (3)pain management (3)camp (3)il-6 (3)neuronal survival (3)erk (3)hypoxia (3)interleukin-6 (3)estrogen (3)amyloid (3)neural development (3)intervention (3)neurobehavioral (3)voiding dysfunction (3)bioinformatics (3)metabolic (3)immunomodulation (3)ischemia (3)mitophagy (3)long-term potentiation (3)extracellular matrix (3)chemotherapy (3)brain function (3)psilocybin (3)microbiome (3)neuroendocrine (3)endocrine (3)cytokines (3)mouse model (3)neuropsychiatric (3)gastrointestinal (3)psychiatric disorders (3)sciatic nerve injury (3)anxiety disorders (3)hyperlipidemia (3)neurobiological (3)nerve growth factor (2)neuronal function (2)developmental toxicity (2)neural (2)gut health (2)biological (2)immunology (2)camkii (2)excitotoxicity (2)electrophysiological (2)urinary biomarkers (2)val66met polymorphism (2)behavioral (2)neuronal development (2)sleep deprivation (2)alpha-synuclein (2)neurological deficits (2)neuropsychiatry (2)empagliflozin (2)p2x4r (2)psychiatric disorder (2)cytokine (2)physiology (2)polyphenol (2)western diet (2)amnesia (2)calcium (2)multi-omics (2)gene therapy (2)neural stem cells (2)magnetic stimulation (2)exercise interventions (2)generalized anxiety disorder (2)serotonergic (2)yoga (2)microglial polarization (2)ischemic brain injury (2)mdd (2)in vivo (2)suicide (2)pathogenesis (2)anesthesia (2)cell death (2)substance use disorders (2)skeletal muscle (2)lead (2)radiotherapy (2)cardiology (2)5-ht (2)lactate (2)lipopolysaccharide (2)inflammatory (2)intermittent fasting (2)brain-gut axis (2)microgravity (2)mindfulness (2)hippocampal bdnf (2)hypertension (2)immunomodulatory (2)flavonoid (2)bone marrow (2)polyunsaturated fatty acids (2)ganoderma lucidum (2)pain (2)high-fat diet (2)gsk-3β (2)tissue engineering (2)adhd (2)il-10 (2)ampk (2)pink1 (2)microglial activation (2)muscle atrophy (2)amplitude (2)peripheral neuropathy (2)tissue plasminogen activator (2)metabolic health (2)healthy aging (2)wild (1)protein kinase (1)pesticide (1)brain abnormalities (1)immune (1)neural health (1)apoe (1)plant-based (1)cellular models (1)neurodevelopmental trajectories (1)synthesis (1)neurobehavioral toxicity (1)cas9 (1)histology (1)electrical stimulation (1)microglial dysfunction (1)hippocampal neurogenesis (1)plasticity (1)glutamatergic (1)phytochemical (1)urinary ngf (1)muscle weakness (1)gα (1)probdnf (1)stem cell therapy (1)nogo-a (1)schwann cell (1)diabetic neuropathy (1)blood biomarker (1)memantine (1)gs3kβ pathway (1)akt1 (1)nssi (1)ect (1)matrix metalloproteinases (1)nme3 (1)biology (1)platelet activation (1)whole-body vibration (1)gestation (1)neuronal plasticity (1)brain barriers (1)neurotransmitter systems (1)biomedicine (1)excipient selection (1)misa (1)genetic polymorphism (1)gsк-3β (1)bayesian network meta-analysis (1)addictive behaviors (1)motor neurons (1)chemical (1)tlr4 (1)psychotherapy (1)plga (1)atrazine (1)induced pluripotent stem cells (1)processed products (1)mental illness (1)nr2b (1)dendritic atrophy (1)domestication (1)adverse childhood experiences (1)hydrophobic interior (1)gestational intermittent hypoxia (1)neuropathy (1)calcineurin (1)sepsis-associated brain injury (1)gdnf (1)crispr (1)becn1 (1)appetite (1)derivatives (1)pediatric (1)nanocage (1)fibromyalgia (1)omega-3 fatty acids (1)paroxetine (1)mri (1)methyl donor (1)neuromodulatory (1)embryo development (1)case management (1)brain aging (1)bcl-2 (1)mettl3 (1)htr2c (1)psychological disorders (1)neurite outgrowth (1)erythropoietin (1)mastication (1)proteolytic processing (1)brain distribution (1)methylation (1)mental disorder (1)intestinal flora (1)pet (1)histone deacetylase (1)gut microbiome (1)proteome (1)klotho (1)attention deficit hyperactivity disorder (1)synthetic cannabinoid (1)human health (1)gene (1)metaplasticity (1)pkb (1)neurotherapeutics (1)sciatic nerve ligation (1)play behaviour (1)pediatric motor disorder (1)eeg (1)mood (1)cxcr4 (1)de novo lipogenesis (1)ultrasound (1)psychiatric therapies (1)nf-kappa b (1)excitatory synapses (1)hap1 (1)therapy (1)il6 (1)neat1 (1)pppar (1)surgical management (1)biochemical role (1)interleukins (1)agrochemical (1)calcium channels (1)neuronal activation (1)protein (1)pathophenotypes (1)glycation (1)dyspnea (1)genomics (1)epidemiology (1)acetylcholinesterase (1)polymorphic variants (1)thiazole (1)perinatal programming (1)neural pathways (1)degradation (1)uveitis (1)synthetic opioid (1)nanocarriers (1)vitamin d3 (1)metabolic dysfunction (1)astroglia (1)pparα (1)pfas (1)glial cells (1)ace2 (1)muscle (1)network (1)uhplc-q-tof-ms/ms (1)sglt2 inhibitor (1)biological aging (1)biochemical analysis (1)astrobiology (1)microbiota-gut-brain axis (1)local translation (1)wharton's jelly (1)essential oil (1)upper motor neuron (1)vulnerability (1)visceral pain (1)adolescence (1)histological damage (1)amyk (1)systemic (1)neural alterations (1)maoa (1)neuroprotectants (1)metabolic flexibility (1)polycystic ovary syndrome (1)neuroprotectors (1)trk (1)genotype (1)migration (1)brain metastases (1)jak2 (1)neuron-microglia interactions (1)behavioral disorders (1)hsd10 (1)aging brain (1)neurotoxicants (1)cell biology (1)neurological function (1)pkr inhibition (1)mict (1)antipsychotic (1)child mental disorder (1)blood brain barrier (1)stat3 (1)ipsc-derived neurons (1)cannabis (1)sepsis-associated encephalopathy (1)functional (1)olfaction (1)protein design (1)neurons (1)genetic background (1)axon growth (1)metformin (1)atf4 (1)blood-based biomarkers (1)multisystem (1)neutrophil extracellular traps (1)cd4 (1)phenolic acid (1)tissue inhibitors of metalloproteinases (1)inflammasome (1)obstetrics (1)fat oxidation (1)ondansetron (1)physical function (1)ipsc (1)ythdf1 (1)glymphatic function (1)immune system (1)nutritional strategies (1)anesthetics (1)ich (1)electroencephalogram (1)rodent models (1)in vivo study (1)phthalates (1)physiotherapy (1)nlrp3 (1)electroporation (1)older adults (1)sexual dysfunction (1)mice (1)sesquiterpenoid (1)fibrinolytic (1)gut-brain interactions (1)n-acetylcysteine (1)body weight (1)mfn2 (1)rat brain (1)hiit (1)inflammatory process (1)spinal disc (1)pacap (1)opioid use (1)ayahuasca (1)genetic risk factor (1)pkc delta (1)endothelial cells (1)lactation (1)hepatocellular carcinoma (1)cell viability (1)necrotic cell death (1)offspring behavior (1)cholinergic dysfunction (1)neurobiomarkers (1)neurotrophin-3 (1)canagliflozin (1)anxiety disorder (1)orthopedic fixation (1)neurodevelopmental biology (1)fragile x syndrome (1)npas4 (1)mesoporous silica (1)cardioprotective (1)hydrocephalus (1)neurological disorder (1)microbiomics (1)nanotherapeutics (1)tubulin (1)neuroinflammatory signalling (1)sineup (1)p75ntr (1)8-iso-pgf2α (1)diabetic neuropathic pain (1)lumbrokinase (1)nlrp3 inflammasome (1)neural organoid (1)neurobiochemistry (1)photoplethysmography (1)cadmium (1)fibroblast-growth factor-21 (1)bulimia (1)calcium-binding protein (1)nursing intervention (1)lipid rafts (1)hallucinogens (1)immune checkpoint (1)trka (1)biological markers (1)social interaction (1)systemic inflammation (1)passive smoking (1)atp production (1)nad (1)biological pathways (1)endocrine disorder (1)decline (1)anxiolytic (1)translation (1)kinases (1)personalized medicine (1)protein formulation (1)vagus nerve (1)carbon dots (1)aerobic (1)in vivo efficacy (1)polyphenols (1)motivational behaviors (1)gonadal hormones (1)nanotechnology (1)neurological growth (1)mitogen-activated protein kinase (1)cannabidiol (1)neuronal degeneration (1)oxidative damage (1)public health (1)radiation-induced brain injury (1)cholinergic (1)therapeutics (1)meditation (1)salmon (1)gut brain axis (1)chemokines (1)toxoplasma gondii (1)omics (1)bdnf/trkb pathway (1)neuroanatomy (1)hepatoprotective (1)nanofibers (1)growth factor (1)dietary triglyceride (1)eating behavior (1)tgf-β (1)homing (1)neuropsychology (1)visual stimulation (1)histone (1)t cells (1)diabetic ischemic brain injury (1)bax (1)behavioral performance (1)prkn (1)metabolic alterations (1)stem cell (1)axon guidance (1)sumoylation (1)acd (1)erbb4 inhibitor (1)two-hit model (1)perk (1)tug1 (1)gene activation (1)tea polyphenols (1)tcm (1)developmental neurotoxicity (1)hormonal (1)plasmin (1)emotion axis (1)bdnf pathway (1)mmp-9 (1)heavy metal (1)histologic analysis (1)platelet factor 4 (1)fisetin (1)neurobehavioral deficits (1)anaerobic exercise (1)hypoxanthine (1)motor function (1)hippocampal neurons (1)psychedelic (1)nutritional psychiatry (1)nerve injury (1)brain-derived neurotrophic factors (1)behaviors (1)mct oil (1)hippocampal plasticity (1)hippocampal development (1)kcc2 (1)peripheral blood mononuclear cells (1)ecb (1)pcl (1)exercise intervention (1)glial scarring (1)ovine (1)lung-brain axis (1)hyperventilation syndrome (1)hbv (1)endocannabinoid pathways (1)geriatrics (1)neonatal brain proteomics (1)muscle pain (1)etiology (1)weightlessness (1)biodegradable materials (1)ho-1 (1)pain subtypes (1)cxcl12 (1)bdnf signalling (1)p2x7r (1)salivary gland (1)cholesterol (1)vitamin d (1)behavior (1)nmda (1)genetic (1)sociodemographic factors (1)neuroprotective properties (1)ethanol (1)oral delivery (1)suicidal ideation (1)neurophysiology (1)synovial fibroblasts (1)translational (1)bioactivity (1)function (1)neural stimulation (1)muscle function (1)ophthalmology (1)gene-tbi interactions (1)macrophages (1)cannabinoid (1)fatty acids (1)piezoelectric (1)tms (1)hepatic encephalopathy (1)mood disorders (1)tph2 (1)cardiometabolic disease (1)psychological (1)single-nucleotide variants (1)schwann cells (1)euglena gracilis (1)inflammatory bowel disease (1)intestinal barrier (1)emotional disorders (1)hyperammonemia (1)5-ht pathway (1)app (1)sleep (1)olfactory system (1)neurovegetative (1)beta-glucan (1)lithium chloride (1)psychobiotics (1)brainstem (1)neuronal growth (1)glioma (1)apolipoprotein e (1)psychotropic (1)substance use disorder (1)neurobiological alterations (1)dendritic morphology (1)b-cell lymphoma 2 (1)puberty (1)cmd (1)electromagnetic field (1)neurochemicals (1)pgc1α (1)low back pain (1)dheas (1)biological sciences (1)intranasal delivery (1)neurotrophic hypothesis (1)cbt (1)sik1 (1)magnetically targeted (1)motor neuron disease (1)visceral hypersensitivity (1)psychiatric genetics (1)drp1 (1)butyrate (1)six3 (1)triclocarban (1)proteomic clustering (1)pharmaceutical (1)cellular nerve damage (1)parkin (1)sciatic nerve (1)pediatrics (1)sepsis (1)pcr (1)traditional uyghur medicine (1)murine model (1)bace1 (1)liquid crystalline (1)gwas (1)neuroblastoma cells (1)signalling pathway (1)brain oxygenation (1)paxillin (1)inflammatory markers (1)neural damage (1)mass spectrometry (1)sleep-promoting (1)monocytes (1)mh (1)sex hormones (1)brain biomarkers (1)immune activation (1)glutamatergic system (1)akt pathway (1)pituitary gland (1)neurochemistry (1)phytochemical analysis (1)plant (1)behavioral deficits (1)tnfα (1)psychiatric (1)peripheral nerve injury (1)clearance system (1)acrylamide (1)behavioral dysfunction (1)gut-hippocampus axis (1)neonatal development (1)vitamin c (1)ppparα (1)uflc-q-tof-ms/ms (1)stagnant phlegm syndrome (1)neurodelivery (1)cav1 (1)metabolic processes (1)gpr40 (1)na/k-atpase (1)nuclear translocation (1)nanoemulsion (1)pericytes (1)p2y1r (1)next-generation sequencing (1)neuroactive lignan (1)food intake (1)neuronal injury (1)muscle denervation (1)inflammatory pathways (1)sox5 (1)herbicide (1)neuroma (1)maya-mestizo population (1)dexras1 (1)msc (1)microcystin (1)amyloid plaque (1)cardiometabolic (1)rat models (1)val66met (1)rock1 (1)plasma technology (1)statins (1)bdnf-trkb pathway (1)mendelian randomization (1)protein kinase b (1)neural plasticity (1)oxidative balance (1)spleen-kidney deficiency (1)prisma (1)metabolic function (1)proinflammatory cytokines (1)antioxidative (1)multiple system atrophy (1)neurobehavior (1)mcao (1)herbal medicine (1)eating disorders (1)brain plasticity (1)hyperglycemia (1)visual function (1)peripheral brain-derived neurotrophic factor (1)lithium (1)dry eye model (1)hepatocyte (1)tnf-α (1)proteases (1)neurological health (1)steroid hormones (1)dendritic spine (1)uhplc-qtof-ms (1)social memory (1)perineuronal networks (1)phytoestrogen (1)childhood obesity (1)lc-ms (1)microvesicles (1)caspase-4 (1)inflammaging (1)muscle-brain axis (1)spions (1)therapeutic implications (1)adolescent brain (1)rotenone (1)metabolic syndrome (1)no (1)lineage (1)neural network (1)phq-9 (1)lipid-lowering (1)gene mutations (1)biochemical (1)pka (1)central sensitization (1)matrix metalloproteases (1)risperidone (1)morphological deficits (1)panax ginseng (1)bioprinted (1)neurotoxicity-associated metabolic alterations (1)polymorphisms (1)minocycline (1)ntrk (1)lcn2 (1)behavioral science (1)liver injury (1)pituitary (1)biophysics (1)cholinergic function (1)orthopedics (1)neural tissue (1)hippocampal injury (1)gastric ulcer (1)vitality (1)space medicine (1)igf-1 (1)intrinsic capacity (1)central nervous system disorders (1)neurodevelopmental studies (1)single-nucleotide polymorphisms (1)fasd (1)polygalae radix (1)exerkines (1)pathophysiological interactions (1)walking (1)chemobrain (1)neural function (1)ingestion (1)bangladeshi population (1)urodynamics (1)aβ plaques (1)immuno-modulation (1)pathway (1)neuroendocrinology (1)supplementation (1)brain tissue (1)cardiotoxicity (1)mglur5 (1)acetylation (1)microplastic (1)therapeutic perspectives (1)methylxanthine (1)naphthoquinone (1)myokine (1)analgesia (1)gst (1)choroid plexus (1)plasma biomarkers (1)glutamatergic pathways (1)biomaterials (1)global health (1)inhibitor (1)
⚗️ Metals 1041
▸ Metals — Other (620)
neuroscience (64)cognitive function (30)synaptic plasticity (25)stress (15)antidepressant (14)pharmacology (11)cognitive dysfunction (10)toxicology (9)cognition (9)serotonin (8)major depressive disorder (7)molecular biology (7)spinal cord injury (7)prefrontal cortex (7)chronic stress (6)autism spectrum disorder (6)chronic pain (6)exosomes (6)ptsd (6)cognitive (6)irisin (5)pregnancy (5)memory impairment (5)network pharmacology (5)cognitive performance (5)endoplasmic reticulum stress (5)neuropharmacology (5)environmental enrichment (4)homeostasis (4)oncology (4)neuroprotective effects (4)traumatic brain injury (4)molecular mechanisms (4)depressive disorder (4)cardiovascular (4)psychopharmacology (4)neuroregeneration (4)resveratrol (4)post-traumatic stress disorder (4)chitosan (4)affective disorders (3)osteoporosis (3)insomnia (3)high-intensity interval training (3)neurobiological mechanisms (3)serum (3)treatment-resistant depression (3)mirna (3)nerve regeneration (3)animal model (3)transcriptomics (3)acupuncture (3)sarcopenia (3)molecular dynamics (3)molecular (3)molecular docking (3)autism (3)rehabilitation (3)electroconvulsive therapy (3)regenerative medicine (3)bioactive compounds (3)prenatal stress (3)melatonin (3)cums (2)tau protein (2)cancer progression (2)er stress (2)glucocorticoid receptor (2)insulin resistance (2)preclinical (2)metabolic regulation (2)quality of life (2)docosahexaenoic acid (2)pharmacogenomics (2)neuroprotective mechanisms (2)gene regulation (2)heart failure (2)alcohol consumption (2)amyotrophic lateral sclerosis (2)ketogenic diet (2)neural circuitry (2)antidepressants (2)trauma (2)retina (2)neurovascular (2)mir-34a-5p (2)ginsenosides (2)stroke recovery (2)transcriptome (2)transcranial magnetic stimulation (2)systematic review (2)molecular pathways (2)regulatory mechanisms (2)executive function (2)postoperative care (2)neuroprotective effect (2)corticosterone (2)post-stroke depression (2)retinal ganglion cells (2)premature ejaculation (2)cognitive recovery (2)selenium (2)learning (2)pharmacological (2)glucagon-like peptide-1 (2)functional recovery (2)circadian rhythms (2)endocrine disruptors (2)early-life stress (2)axonal regeneration (2)naringenin (2)cognitive deficits (2)endoplasmic reticulum (2)alcohol (2)depressive behaviors (2)peripheral nerve regeneration (2)nmda receptor (2)cognitive health (2)cortisol (2)cytoskeleton (2)postoperative cognitive dysfunction (2)infralimbic cortex (2)cerebrum (2)cortical neurons (2)synaptic dysfunction (2)molecular targets (2)benzalkonium chloride (2)prebiotics (2)mild cognitive impairment (2)ethnopharmacology (2)cognitive functions (2)regeneration (2)tau (1)viral infections (1)stress responses (1)physicochemical characterization (1)brain immunity (1)correction (1)retinoic acid (1)post-translational modification (1)exposure (1)lucidenic acid a (1)hepatic steatosis (1)dietary regulation (1)nerve conduits (1)environmental pollutants (1)perigestational opioid exposure (1)meta-regression (1)mechanosensory hair cells (1)hippocampal ca2 region (1)neural precursors (1)photoreceptors (1)anaerobic glycolytic flux (1)respiratory (1)randomized controlled trials (1)ischemic postconditioning (1)molecular changes (1)growth cones (1)total abdominal irradiation (1)cardiovascular disease (1)aggression (1)gold nanoparticles (1)circrna (1)preclinical evidence (1)traumatic injury (1)dopamine d2 receptor (1)progressive (1)psychological trauma (1)drug metabolism (1)neural structure (1)synaptic transmission (1)laquinimod (1)preterm birth (1)resilience (1)peptide design (1)fermented food (1)spatial learning (1)complications (1)allergic contact dermatitis (1)particulate matter (1)corticospinal tract (1)chronic restraint stress (1)cerebellum (1)hepatitis b virus (1)copd (1)post-stroke cognitive impairment (1)tryptophan metabolism (1)ginsenoside (1)auricular vagus nerve stimulation (1)biosynthesis (1)scoping review (1)vascular endothelium (1)opioid prescription (1)mir-381-3p (1)learning-memory (1)fetal alcohol spectrum disorders (1)emotion perception (1)hippocampal structure (1)cell communication (1)sedative-hypnotic effects (1)amniotic fluid stem cell (1)cardiovascular disorders (1)nerve guidance conduits (1)regulatory network (1)synaptic impairment (1)peroxisome proliferator-activated receptor alpha (1)neurocognitive impairment (1)aquatic ecosystems (1)fibronectin type iii domain-containing protein 5 (1)phosphorylated tau (1)oxygen-glucose deprivation (1)chronicity (1)intracerebral hemorrhage (1)osteosarcopenia (1)behavioral responses (1)anorexia (1)selective serotonin reuptake inhibitors (1)stable love relationships (1)psychological treatment (1)hippocampal regeneration (1)redox homeostasis (1)neuroprotective molecules (1)neurovascular plasticity (1)neuropeptide (1)irradiation (1)hemorheological parameters (1)cellular mechanisms (1)cognitive flexibility (1)astrocytic disruption (1)alcohol dependence (1)stroke treatment (1)irritable bowel syndrome (1)seizure susceptibility (1)immune reactions (1)tumor necrosis factor alpha (1)mirnas (1)menopausal (1)microbiota dysbiosis (1)bed rest (1)nicotine (1)bone loss (1)cubosome formulation (1)post traumatic stress disorder (1)vascular dysfunction (1)hyperandrogenism (1)pd-1 (1)hippocampal neuronal apoptosis (1)prenatal exposure (1)pyroptosis (1)withaferin a (1)glycolysis (1)microenvironment (1)redox balance (1)circadian rhythm (1)olfactory exposure (1)nose-to-brain delivery (1)neurocognitive outcomes (1)sex differences (1)neuro-osteogenic microenvironment (1)acute ischemic stroke (1)psychedelic drugs (1)sinomenine (1)secretory protein (1)maladaptive neuroplasticity (1)facial recognition (1)stress disorder (1)carnosine (1)synaptic deficits (1)mir-146a-3p (1)regulation (1)ferritin (1)protein secretion (1)scopolamine-induced amnesia (1)randomized controlled trial (1)principal component analysis (1)appetite regulation (1)psychiatric comorbidities (1)environmental toxicology (1)gynecology (1)hif-1α-epo/camp-creb-bdnf pathway (1)depressive states (1)learning process (1)neural regeneration (1)cardiac arrest (1)psychological outcomes (1)affective states (1)gut dysbiosis (1)long non-coding rnas (1)prefrontal-limbic connectivity (1)psychological reaction (1)extremely low-frequency magnetic field (1)clinical assessment (1)microglial exosomes (1)neurotoxicology (1)epileptogenesis (1)clinical trial (1)anabolic-androgenic steroid (1)ethnic medicine (1)mitochondrial calcium uniporter (1)weight loss (1)amitriptyline (1)stress responsivity (1)serotonergic circuit (1)lps-induced depression (1)locomotion (1)steroidal saponin (1)aquatic organisms (1)correlation (1)drug response (1)transcriptomic (1)long non-coding rna (1)rheumatoid arthritis (1)rem theta (1)absorption (1)chronic heart failure (1)fentanyl administration (1)molecular toxicology (1)vascular cognitive impairment (1)motor impairment (1)adipose-derived stem cells (1)neuro-related disorders (1)emotional regulation (1)restraint stress (1)regenerative capabilities (1)antinociceptive (1)cerebral palsy (1)cerebral infarction (1)normal pressure hydrocephalus (1)positron emission tomography (1)bioengineered delivery system (1)adenosine (1)connexin43 (1)immunoregulation (1)comorbid (1)cerebrovascular disease (1)in silico (1)moderate-intensity continuous training (1)cognitive improvement (1)stress-induced depressive behaviors (1)drug delivery (1)lycopene delivery (1)host-virus interactions (1)phosphatidic acid (1)sirt1 (1)neuroserpin (1)heat stress (1)macular degeneration (1)medial prefrontal cortex (1)intranasal drug delivery (1)early diagnosis (1)rem sleep behavior disorder (1)seizures (1)psychosocial (1)prenatal supplementation (1)adeno-associated virus (1)neurotoxic effects (1)proanthocyanidins (1)neurocognitive (1)anti-inflammatory effects (1)gestational opioid exposure (1)nociceptive sensitization (1)stress axis regulation (1)anthocyanins (1)pruritus (1)phlorotannin (1)high intensity interval training (1)prosopis cineraria (1)psychosis (1)constipation (1)psychedelic compounds (1)delphinidin (1)myostatin (1)triterpenoid saponins (1)limbic structures (1)osteoblast (1)bdnf expression (1)poly(lactic-co-glycolic acid) (1)korean population (1)neuroimmune crosstalk (1)chronic diseases (1)low birthweight (1)α7 nicotinic acetylcholine receptor (1)protein quality control (1)peptide hydrogel (1)fecal calprotectin (1)metabolic adaptation (1)single-cell transcriptomics (1)cell differentiation (1)neurogenic bladder (1)hippocampal synaptic proteins (1)chemoresistance (1)herb pair (1)chronotropic incompetence (1)autism-like behavior (1)testicular health (1)aggressive behavior (1)allodynia (1)obstructive sleep apnea (1)opioid overdose (1)gold coast criteria (1)n-methyl-d-aspartate receptor (1)psychological stress (1)betulinic acid (1)retinal degeneration (1)depressive pathologies (1)traumatic event (1)ros (1)extremely low-frequency electromagnetic field (1)cognitive impairments (1)chronic toxoplasmosis (1)dacomitinib (1)serotonin 5-ht2a receptor (1)pulmonary fibrosis (1)psychostimulant (1)chronic unpredictable mild stress (1)tobacco smoke (1)radiofrequency electromagnetic fields (1)fetal brain development (1)sedative-hypnotic effect (1)social buffering (1)depressive disorders (1)epigenetic dysregulation (1)neuroimmune circuits (1)childhood growth restriction (1)resolvin d1 (1)molecular design (1)glp-1 receptor agonists (1)brain-gut homeostasis (1)neurotrophic adaptation (1)liver failure (1)creb pathway (1)diclofenac (1)n6-methyladenosine (1)immune mechanisms (1)laminin (1)cerebrovascular accidents (1)suicide attempt (1)neural repair (1)synaptic (1)adverse outcome pathway (1)opioid receptors (1)memory impairments (1)fibrotic remodeling (1)neuronal communication (1)appetite control (1)outcomes (1)hypothalamus-pituitary-adrenal axis (1)serum bdnf levels (1)lung homeostasis (1)perioperative neurocognitive disorders (1)cognitive training (1)melatonin receptor (1)adolescent social isolation stress (1)cognitive therapy (1)fear memory (1)osseointegration (1)musculoskeletal system (1)colitis (1)autoimmune uveitis (1)light treatment (1)cerebral protection (1)neurotrophic dysregulation (1)ingredient (1)developmental neurotoxicology (1)transcriptional changes (1)neurosteroids (1)environmental conditions (1)orthostatic hypotension (1)pathological microenvironment (1)autologous serum (1)physiological resilience (1)spatial transcriptomics (1)function recovery (1)age-related macular degeneration (1)seizure (1)mangiferin (1)preclinical models (1)herpes simplex virus (1)exosome-based therapy (1)peptides (1)melanocortin (1)tau phosphorylation (1)tumor necrosis factor (1)eicosapentaenoic acid (1)neural circuit (1)hypothalamic-pituitary-adrenal axis (1)brain structure (1)phosphatidylserine (1)irák1 (1)colorectal cancer (1)perinatal depression (1)learning ability (1)allostatic load (1)adolescent depression (1)creatine supplementation (1)affective dysfunction (1)non-pharmacological interventions (1)personal care products (1)diagnosis (1)unfolded protein response (1)antidepressant mechanisms (1)cerebral hemorrhage (1)autophagic pathway (1)nanocomposite hydrogel (1)causal relationship (1)fear extinction (1)neuropeptide s (1)nociceptive responses (1)dpd-4 inhibitors (1)traumatic stress disorder (1)colon cancer (1)tau hyperphosphorylation (1)tyrosine kinase receptor b (1)ecosystems (1)reproductive physiology (1)stress regulation (1)motor learning (1)disease-syndrome combined model (1)methionine-choline-deficient diet (1)s-nitrosylation (1)neurocognitive disorders (1)postmenopausal women (1)neural recovery (1)kaempferol (1)postoperative delirium (1)receptor (1)social cognition (1)neurocognition (1)environmental (1)hcortisolaemia (1)integrated stress response (1)systemic effects (1)antiretroviral therapy (1)adenosine receptor (1)late-life cognitive decline (1)traumatic memories (1)energy homeostasis (1)antidepressant effect (1)physiological adaptations (1)inflammatory responses (1)tissue architecture (1)vascularization (1)neuroimmune responses (1)human respiratory syncytial virus (1)vision loss (1)rapid antidepressant effects (1)tau pathology (1)drug release (1)signal peptide (1)noncommunicable diseases (1)electrospun (1)alcohol-induced cognitive impairment (1)vasoactive intestinal polypeptide (1)cognitive behavior (1)hypothalamic pituitary adrenal axis (1)machine learning (1)hypothalamic-pituitary adrenal axis (1)parkinsonism (1)cognitive resilience (1)impairment (1)experimental autoimmune uveoretinitis (1)precursor state (1)hmg-coa reductase inhibitors (1)tumor necrosis factor-α (1)relationship (1)cognitive aging (1)clinical psychology (1)antidepressant activity (1)optic nerve injury (1)mechanistic (1)vascular maturation (1)biomechanics (1)aerospace medicine (1)oncogenic drivers (1)differentiation (1)resistance training (1)paraventricular nucleus (1)ecotoxicity (1)synaptic homeostasis (1)environmental concern (1)bdnf/creb pathway (1)creb phosphorylation (1)mood dysregulation (1)nitrous oxide (1)dentate gyrus (1)paternal exposure (1)behavioral despair (1)nicotine exposure (1)lactobacillus plantarum (1)electroacupuncture (1)female mice (1)fetal neural development (1)tropomyosin receptor kinase b (1)environmental contaminants (1)differentiation protocols (1)magnetic resonance imaging (1)reward processing (1)arsenic (1)steroid effects (1)diosgenin (1)stress hormone (1)oral administration (1)hemorheology (1)synaptic models (1)reversal learning (1)synaptic signaling (1)cognitive outcomes (1)presynaptic (1)magnetic field exposure (1)ischemia reperfusion injury (1)nitric oxide (1)toxoplasmosis (1)tyrosine kinase inhibitors (1)acute hepatitis (1)glucagon-like peptide-1 receptor agonists (1)somatosensory cortex (1)serotonin pathway (1)biological effects (1)cyanidin (1)breast cancer (1)
💊 Drugs 4

🔍 Filters

651 articles with selected tags
X Lin, D Wells · 1997 · DNA sequence : the journal of DNA sequencing and mapping · added 2026-04-24
We have cloned and sequenced the mouse cDNA homologous to the human Hereditary Multiple Exostoses (EXT1) gene. The mouse homolog shows 94% similarity at the nucleotide level and 99% similarity at the Show more
We have cloned and sequenced the mouse cDNA homologous to the human Hereditary Multiple Exostoses (EXT1) gene. The mouse homolog shows 94% similarity at the nucleotide level and 99% similarity at the protein level compared to the human gene. The 5' UTRs are unusually conserved for non-coding sequences showing 94% similarity compared to 80% for the 3' UTRs. The high level of evolutionary conservation between the EXT1 proteins as well as the 5' UTR suggests that each plays an important and related role in both species. Show less
no PDF DOI: 10.3109/10425179709034035
EXT1
D R Lohmann, K Buiting, H J Lüdecke +1 more · 1997 · Cytogenetics and cell genetics · added 2026-04-24
We have cloned and sequenced the murine homologue of the human EXT1 gene. At the protein level, these genes show almost complete identity as divergence is limited to only 5 amino acid positions that a Show more
We have cloned and sequenced the murine homologue of the human EXT1 gene. At the protein level, these genes show almost complete identity as divergence is limited to only 5 amino acid positions that are scattered about the whole sequence. In addition, similarity searches identified a protein from chromosome III of C. elegans that shows significant similarity to the human and murine EXT/Ext genes. Using high resolution backcross mapping, the murine Ext1 was mapped at 26.55 cM between D15Mit143 and D15Mit153 on mouse chromosome 15. Therefore, Ext1 is part of an evolutionarily conserved linkage group including SDC2/Hspg1, TRHR/Trhr, EXT1/Ext1, MYC/Myc, and TG/Tgn. Show less
no PDF DOI: 10.1159/000134536
EXT1
D Stickens, G A Evans · 1997 · Biochemical and molecular medicine · added 2026-04-24
Multiple exostoses is a polygenic disease of bone formation and development characterized by the presence of cartilage-capped osseous projections emanating from the end of the long bones. Two members Show more
Multiple exostoses is a polygenic disease of bone formation and development characterized by the presence of cartilage-capped osseous projections emanating from the end of the long bones. Two members of a recently defined multigene family of proteins (EXT1 and 2) were shown to be involved in this disease. To investigate the evolutionary relatedness of EXT genes across species we isolated the mouse EXT2 cDNA. As in the human counterpart, the mouse EXT2 cDNA contains an open reading frame of 2154 bp encoding a predicted protein of 718 amino acids. The nucleic acid sequence is 87% identical to the human EXT2 transcript, resulting in an amino acid sequence which is 95% identical to the human protein. The mouse EXT2 gene also shows significant sequence similarity to the mouse and human EXT1 gene. Northern blot analysis shows that this gene is expressed in early stages of embryonic development, and in situ hybridizations suggest that EXT2 plays a role in limb development. The identification of the mouse EXT2 gene will allow functional analysis through insertional inactivation and reverse genetics in mice in order to better understand the formation of exostoses during bone formation. Show less
no PDF DOI: 10.1006/bmme.1997.2588
EXT1
W Wuyts, W Van Hul, J Hendrickx +7 more · 1997 · European journal of human genetics : EJHG · added 2026-04-24
Recently, two homologous genes, EXT1 and EXT2, with a putative tumor suppressor function have been described. Mutations in both genes are responsible for multiple exostosis syndrome (EXT), an autosoma Show more
Recently, two homologous genes, EXT1 and EXT2, with a putative tumor suppressor function have been described. Mutations in both genes are responsible for multiple exostosis syndrome (EXT), an autosomal dominant condition characterized by the presence of multiple osteochondromas, bony excrescences that sometimes undergo malignant transformation to chondrosarcoma. This family of EXT genes has been extended by the identification of an EXT-like (EXTL) gene showing a high degree of homology with the EXT genes. We report here a second EXT-like gene (EXTL2) which is homologous to the EXT and EXTL genes. EXTL2 consists of 5 exons encoding an ubiquitously expressed protein of 330 amino acids. In addition, a putative pseudogene, EXTL2P was also identified. The EXTL2 gene was assigned to chromosome 1p11-p12, whereas EXTL2P was mapped on chromosome 2q24-q31. Show less
no PDF
EXT1
D E Wells, A Hill, X Lin +3 more · 1997 · Human genetics · Springer · added 2026-04-24
Hereditary multiple exostoses (EXT) is a genetically heterogeneous bone disorder caused by genes segregating on human chromosomes 8, 11, and 19 and designated EXT1, EXT2 and EXT3, respectively. Recent Show more
Hereditary multiple exostoses (EXT) is a genetically heterogeneous bone disorder caused by genes segregating on human chromosomes 8, 11, and 19 and designated EXT1, EXT2 and EXT3, respectively. Recently, the EXT1 gene has been isolated and partially characterized and appears to encode a tumor suppressor gene. We have identified six mutations in the human EXT1 gene from six unrelated multiple exostoses families segregating for the EXT gene on chromosome 8. One of the mutations we detected is the same 1-bp deletion in exon 6 that was previously reported in two independent EXT families. The other five mutations, in exons 1, 6, 9, and the splice junction at the 3' end of exon 2, are novel. In each case, the mutation is likely to result in a truncated or nonfunctional EXT1 protein. These results corroborate and extend the previous report of mutations in this gene in two EXT families, and provide additional support for the EXT1 gene as the cause of hereditary multiple exostoses in families showing linkage to chromosome 8. Show less
no PDF DOI: 10.1007/s004390050415
EXT1
J T Hecht, D Hogue, Y Wang +6 more · 1997 · American journal of human genetics · added 2026-04-24
Hereditary multiple exostoses (EXT) is an autosomal dominant disorder characterized by the formation of cartilage-capped prominences that develop from the growth centers of the long bones. EXT is gene Show more
Hereditary multiple exostoses (EXT) is an autosomal dominant disorder characterized by the formation of cartilage-capped prominences that develop from the growth centers of the long bones. EXT is genetically heterogeneous, with three loci, currently identified on chromosomes 8q24.1, 11p13, and 19q. The EXT1 gene, located on chromosome 8q24.1, has been cloned and is encoded by a 3.4-kb cDNA. Five mutations in the EXT1 gene have been identified--four germ-line mutations, including two unrelated families with the same mutation, and one somatic mutation in a patient with chondrosarcoma. Four of the mutations identified resulted in frameshifts and premature termination codons, while the fifth mutation resulted in a substitution of leucine for arginine. Loss of heterozygosity (LOH) analysis of chondrosarcomas and chondroblastomas revealed multiple LOH events at loci on chromosomes 3q, 8q, 10q, and 19q. One sporadic chondrosarcoma demonstrated LOH for EXT1 and EXT3, while a second underwent LOH for EXT2 and chromosome 10. A third chondrosarcoma underwent LOH for EXT1 and chromosome 3q. These results agree with previous findings that mutations at EXT1 and multiple genetic events that include LOH at other loci may be required for the development of chondrosarcoma. Show less
no PDF
EXT1
G A Clines, J A Ashley, S Shah +1 more · 1997 · Genome research · Cold Spring Harbor Laboratory · added 2026-04-24
Hereditary multiple exostoses (EXT) is an autosomal dominant disorder characterized by multiple cartilage-capped outgrowths from the epiphyses of long bones. In some cases, these osteochondromas progr Show more
Hereditary multiple exostoses (EXT) is an autosomal dominant disorder characterized by multiple cartilage-capped outgrowths from the epiphyses of long bones. In some cases, these osteochondromas progress to malignant chondrosarcomas. Alterations in at least three genes (EXT1, EXT2, and EXT3) can cause this disorder. Two of these have been isolated (EXT1 and EXT2) and encode related members of a putative tumor suppressor family. We report here the genomic structure of the human EXT2 gene consisting of 14 exons (plus 2 alternative exons) covering an estimated 108 kb of chromosome 11p11-13. We have derived the DNA sequences at all exon/intron boundaries throughout this gene-information that is important for the detailed study of mutations in EXT2. We have also characterized the mouse EXT2 cDNA and have mapped the mouse locus to chromosome 2 between D2Mit15 and Pax6. This mouse homolog should enable transgenic knockout experiments to be initiated to further elucidate gene function. Interestingly, sequence comparisons reveal that the human and mouse EXT genes have at least two homologs in the invertebrate Caenorhabditis elegans, indicating that they do not function exclusively as regulators of bone growth. This observation opens the way for a functional analysis of these genes in nematodes and other lower organisms. Show less
no PDF DOI: 10.1101/gr.7.4.359
EXT1
Z Piao, H Kim, B K Jeon +2 more · 1997 · Cancer · added 2026-04-24
Hepatocellular carcinoma (HCC) is one of the most common human tumors in Asia and Africa. The molecular genetic changes involving both protooncogenes and tumor suppressor genes are known to be involve Show more
Hepatocellular carcinoma (HCC) is one of the most common human tumors in Asia and Africa. The molecular genetic changes involving both protooncogenes and tumor suppressor genes are known to be involved in hepatocarcinogenesis, but the roles of the known tumor suppressor genes in hepatocarcinogenesis are not fully elucidated. In this study, the authors analyzed the loss of heterozygosity (LOH) of known tumor suppressor genes in HCC and evaluated the relationship between LOH of tumor suppressor genes and clinicopathologic features. The authors assessed the LOH of the 10 known tumor suppressor genes (VHL, APC, EXT1, WT1, Rb1, p53, BRCA1, nm23, DPC4, and DCC) with microsatellite markers in 29 consecutively resected HCC specimens. The authors found frequent LOH of tumor suppressor genes in HCC. Twenty five of 29 cases (86%) had LOH of tumor suppressor genes and 17 cases (59%) had LOHs involving 2-4 tumor suppressor genes. Among the tumor suppressor genes, frequent LOH was noted in the p53 (66%), Rb1 (33%), EXT1 (33%), and APC (20%) genes. LOH of the p53 gene and multiple LOH of the tumor suppressor genes were more frequent in poorly differentiated HCCs (P = 0.02). The LOH of tumor suppressor genes is frequent in HCCs and LOH of the p53 gene and accumulated LOHs are related to poorly differentiated HCC. Abnormalities of the p53 gene or the accumulated abnormalities of the tumor suppressor genes may play a role in the aggressive progression of HCC. Show less
no PDF
EXT1
C Philippe, D E Porter, M E Emerton +3 more · 1997 · American journal of human genetics · added 2026-04-24
Hereditary multiple exostoses (HME), the most frequent of all skeletal dysplasias, is an autosomal dominant disorder characterized by the presence of multiple exostoses localized mainly at the end of Show more
Hereditary multiple exostoses (HME), the most frequent of all skeletal dysplasias, is an autosomal dominant disorder characterized by the presence of multiple exostoses localized mainly at the end of long bones. HME is genetically heterogeneous, with at least three loci, on 8q24.1 (EXT1), 11p11-p13 (EXT2), and 19p (EXT3). Both the EXT1 and EXT2 genes have been cloned recently and define a new family of potential tumor suppressor genes. This is the first study in which mutation screening has been performed for both the EXT1 and EXT2 genes prior to any linkage analysis. We have screened 17 probands with the HME phenotype, for alterations in all translated exons and flanking intronic sequences, in the EXT1 and EXT2 genes, by conformation-sensitive gel electrophoresis. We found the disease-causing mutation in 12 families (70%), 7 (41%) of which have EXT1 mutations and 5 (29%) EXT2 mutations. Together with the previously described 1-bp deletion in exon 6, which is present in 2 of our families, we report five new mutations in EXT1. Two are missense mutations in exon 2 (G339D and R340C), and the other three alterations (a nonsense mutation, a frameshift, and a splicing mutation) are likely to result in truncated nonfunctional proteins. Four new mutations are described in EXT2. A missense mutation (D227N) was found in 2 different families; the other three alterations (two nonsense mutations and one frameshift mutation) lead directly or indirectly to premature stop codons. The missense mutations in EXT1 and EXT2 may pinpoint crucial domains in both proteins and therefore give clues for the understanding of the pathophysiology of this skeletal disorder. Show less
no PDF DOI: 10.1086/515505
EXT1
K Ptaszynski, K H Ramesh, L A Cannizzaro · 1997 · Cancer genetics and cytogenetics · Elsevier · added 2026-04-24
We report cytogenetic findings in a case of grade III chondrosarcoma. Complex clonal chromosome aberrations including monosomy of chromosomes 4, 8, 13, and a consistent t(5;14)(q23;p12) were observed Show more
We report cytogenetic findings in a case of grade III chondrosarcoma. Complex clonal chromosome aberrations including monosomy of chromosomes 4, 8, 13, and a consistent t(5;14)(q23;p12) were observed in all cells. There were no structural or numerical anomalies involving chromosome 12. The complexity of the chromosome aberrations reflect the advanced stage of this chondrosarcoma; we suggest a possible involvement of the EXT1 gene located on chromosome 8. Show less
no PDF DOI: 10.1016/s0165-4608(96)00360-3
EXT1
C A Wise, G A Clines, H Massa +2 more · 1997 · Genome research · Cold Spring Harbor Laboratory · added 2026-04-24
Hereditary multiple exostoses (EXT) is an autosomal dominant disorder characterized by multiple bony outgrowths from the juxtaepiphyseal region of long bones. In a small proportion of cases, these exo Show more
Hereditary multiple exostoses (EXT) is an autosomal dominant disorder characterized by multiple bony outgrowths from the juxtaepiphyseal region of long bones. In a small proportion of cases, these exostoses progress to malignant chondrosarcomas. Genetic linkage of this disorder has been described to three independent loci on chromosomes 8q24.1 (EXT1), 11p11-13 (EXT2), and 19p (EXT-3). The EXT1 and EXT2 genes were isolated recently and show extensive sequence homology to each other. These genes are deleted in exostoses-derived tumors, supporting the hypothesis that they encode tumor suppressors. We have identified a third gene that shows striking sequence similarity to both EXT1 and EXT2 at the nucleotide and amino acid sequence levels, and have derived its entire coding sequence. Although the mRNA transcribed from this gene is similar in size to that from EXT1 and EXT2, its pattern of expression is quite different. We have localized this gene by fluorescence in situ hybridization to metaphase chromosomes and by whole genome radiation hybrid mapping to chromosome 1p36.1 between DIS458 and DIS511, region that frequently shows loss of heterozygosity in a variety of tumor types. This gene, EXTL (for EXT-like), is therefore a new member of the EXT gene family and is a potential candidate for several disease phenotypes. Show less
no PDF DOI: 10.1101/gr.7.1.10
EXT1
L Legeai-Mallet, P Margaritte-Jeannin, M Lemdani +5 more · 1997 · Human genetics · Springer · added 2026-04-24
Hereditary multiple exostoses (EXT) is an autosomal dominant disorder characterized by the presence of multiple cartilage-capped exostoses in the juxta-epiphyseal regions of the long bones. EXT is het Show more
Hereditary multiple exostoses (EXT) is an autosomal dominant disorder characterized by the presence of multiple cartilage-capped exostoses in the juxta-epiphyseal regions of the long bones. EXT is heterogeneous with at least three different locations currently having been identified on chromosomes 8, 11 and 19. We have tested a series of 29 EXT families for possible linkage to the three disease loci and estimated the probability of linkage of the disease to each locus in our series, by using an extension of the admixture test, which makes modelling of heterogeneous monogenic disease feasible. The maximum likelihood was obtained for proportions of 44%, 28% and 28% of families being linked to chromosome 8, 11 and 19, respectively. The a posteriori probability of linkage of the disease to EXT1, EXT2 and EXT3 was greater than 80% for 8/29, 5/29 and 3/29 families, respectively, and did not give evidence of a fourth locus for the disease. The present approach can be generalized to the investigation of genetic heterogeneity in other monogenic diseases, as it simultaneously estimates the location of each disease gene and the proportion of families linked to each locus. Show less
no PDF DOI: 10.1007/s004390050361
EXT1
W Wuyts, W Van Hul, J Wauters +19 more · 1996 · Human molecular genetics · Oxford University Press · added 2026-04-24
Hereditary multiple exostosis (EXT) is an autosomal dominant condition mainly characterized by the presence of multiple exostoses on the long bones. These exostoses are benign cartilaginous tumors (en Show more
Hereditary multiple exostosis (EXT) is an autosomal dominant condition mainly characterized by the presence of multiple exostoses on the long bones. These exostoses are benign cartilaginous tumors (enchondromata). Three different EXT loci on chromosomes 8q (EXT1), 11p (EXT2) and 19p (EXT3) have been reported, and recently the EXT1 gene was identified by positional cloning. To isolate the EXT2 gene, we constructed a contig of yeast artificial chromosomes (YAC) and P1 clones covering the complete EXT2 candidate region on chromosome 11p11-p12. One of the transcribed sequences isolated from this region corresponds to a novel gene with homology to the EXT1 gene, and harbours inactivating mutations in different patients with hereditary multiple exostoses. This indicates that this gene is the EXT2 gene. EXT2 has an open reading frame encoding 718 amino acids with an overall homology of 30.9% with EXT1, suggesting that a family of related genes might be responsible for the development of EXT. Show less
no PDF DOI: 10.1093/hmg/5.10.1547
EXT1
D Stickens, G Clines, D Burbee +6 more · 1996 · Nature genetics · Nature · added 2026-04-24
Hereditary multiple exostoses (EXT) is an autosomal dominant condition characterized by short stature and the development of bony protuberances at the ends of all the long bones. Three genetic locl ha Show more
Hereditary multiple exostoses (EXT) is an autosomal dominant condition characterized by short stature and the development of bony protuberances at the ends of all the long bones. Three genetic locl have been identified by genetic linkage analysis at chromosomes 8q24.1, 11p11-13 and 19p. The EXT1 gene on chromosome 8 was recently identified and characterized. Here, we report the isolation and characterization of the EXT2 gene. This gene shows striking sequence similarity to the EXT1 gene, and we have identified a four base deletion segregating with the phenotype. Both EXT1 and EXT2 show significant homology with one additional expressed sequence tag, defining a new multigene family of proteins with potential tumour suppressor activity. Show less
no PDF DOI: 10.1038/ng0996-25
EXT1
J Ahn, H J Lüdecke, S Lindow +5 more · 1995 · Nature genetics · Nature · added 2026-04-24
Hereditary multiple exostoses is an autosomal dominant disorder that is characterized by short stature and multiple, benign bone tumours. In a majority of families, the genetic defect (EXT1) is linked Show more
Hereditary multiple exostoses is an autosomal dominant disorder that is characterized by short stature and multiple, benign bone tumours. In a majority of families, the genetic defect (EXT1) is linked to the Langer-Giedion syndrome chromosomal region in 8q24.1. From this region we have cloned and characterized a cDNA which spans chromosomal breakpoints previously identified in two multiple exostoses patients. Furthermore, the gene harbours frameshift mutations in affected members of two EXT1 families. The cDNA has a coding region of 2,238 bp with no apparent homology to other known gene sequences and thus its function remains elusive. However, recent studies in sporadic and exostosis-derived chondrosarcomas suggest that the 8q24.1-encoded EXT1 gene may have tumour suppressor function. Show less
no PDF DOI: 10.1038/ng1095-137
EXT1
H J Lüdecke, M J Wagner, J Nardmann +7 more · 1995 · Human molecular genetics · Oxford University Press · added 2026-04-24
The Langer-Giedion syndrome (tricho-rhino-phalangeal syndrome type II, TRPS II) is characterized by craniofacial dysmorphism and skeletal abnormalities. It combines the clinical features of TRPS I and Show more
The Langer-Giedion syndrome (tricho-rhino-phalangeal syndrome type II, TRPS II) is characterized by craniofacial dysmorphism and skeletal abnormalities. It combines the clinical features of TRPS I and multiple cartilaginous exostoses (EXT). We have used YAC cloning, Southern blotting, PCR analysis, and fluorescence in situ hybridization to study chromosome 8 deletions, translocations, an inversion, and an insertion in patients with TRPS I, TRPS II or EXT. Our results indicate that the TRPS gene maps more than 1,000 kb proximal to the EXT1 gene and that both genes are affected in TRPS II. We conclude that TRPS II is not due to pleiotropic effects of mutations in a single gene, but that it is a true contiguous gene syndrome. Show less
no PDF DOI: 10.1093/hmg/4.1.31
EXT1
W H Raskind, E U Conrad, H Chansky +1 more · 1995 · American journal of human genetics · added 2026-04-24
Hereditary multiple exostoses (EXT; MIM 133700) is an autosomal dominant condition characterized by growth of multiple benign cartilage-capped tumors. EXT greatly increases the relative risk to develo Show more
Hereditary multiple exostoses (EXT; MIM 133700) is an autosomal dominant condition characterized by growth of multiple benign cartilage-capped tumors. EXT greatly increases the relative risk to develop chondrosarcoma, although most chondrosarcomas are sporadic. This observation suggests that, like the genes responsible for retinoblastoma and other dominantly inherited cancer susceptibility disorders, the genes that cause EXT may have tumor-suppressor function and may play a role in the pathogenesis of the related sporadic tumors. To investigate this hypothesis, we evaluated chondrosarcomas for loss of constitutional heterozygosity (LOH) at polymorphic loci linked to three recently identified genomic regions containing genes involved in EXT. LOH for markers linked to EXT1 on chromosome 8 was detected in a chondrosarcoma that arose in a man with EXT. Four of 17 sporadic tumors showed LOH for markers linked to EXT1, and 7 showed LOH for markers linked to EXT2 on chromosome 11. In all, LOH was observed for markers linked to EXT1 or EXT2 in 44% of the 18 tumors, whereas heterozygosity was retained for markers on 19p linked to EXT3. These findings support the hypothesis that genes on 8q and the pericentromeric region of 11 have tumor-suppressor function and play a role in the development of chondrosarcomas. Show less
no PDF
EXT1
J T Hecht, D Hogue, L C Strong +3 more · 1995 · American journal of human genetics · added 2026-04-24
Hereditary multiple exostosis (EXT) is an autosomal dominant disorder characterized by bony exostoses at the ends of the long bones. Linkage studies have recently suggested that there are three chromo Show more
Hereditary multiple exostosis (EXT) is an autosomal dominant disorder characterized by bony exostoses at the ends of the long bones. Linkage studies have recently suggested that there are three chromosomal locations for EXT genes, 8q24.1 (EXT1), the pericentric region of 11 (EXT2), and 19p (EXT3). As part of a larger study to determine the frequencies of the three EXT types in the United States, we have ascertained a large multigenerational family with EXT and one family member with a chondrosarcoma. This family demonstrated linkage of the disease to chromosome 11 markers. The constitutional and tumor DNAs from the affected family member were compared using short-tandem-repeat markers from chromosomes 8, 11, and 19. Loss of heterozygosity (LOH) in the tumor was observed for chromosome 8 and 11 markers, but chromosome 19 markers were intact. An apparent deletion of the marker D11S903 was observed in constitutional DNA from all affected individuals and in the tumor sample. These results indicate that the EXT2 gene maps to the region containing marker D11S903, which is flanked by markers D11S1355 and D11S1361. Additional constitutional and chondrosarcoma DNA pairs from six unrelated individuals, two of whom had EXT, were similarly analyzed. One tumor from an individual with EXT demonstrated LOH for chromosome 8 markers, and a person with a sporadic chondrosarcoma was found to have tumor-specific LOH and a homozygous deletion of chromosome 11 markers. These findings suggest that EXT genes may be tumor-suppressor genes and that the initiation of tumor development may follow a multistep model. Show less
no PDF
EXT1
J Hou, J Parrish, H J Lüdecke +7 more · 1995 · Genomics · added 2026-04-24
We have constructed a physical map covering over 4 Mb of human chromosome 8q24.1 and used this map to refine the locations of the genes responsible for Langer-Giedion syndrome. The map is composed of Show more
We have constructed a physical map covering over 4 Mb of human chromosome 8q24.1 and used this map to refine the locations of the genes responsible for Langer-Giedion syndrome. The map is composed of overlapping YAC clones that were identified and ordered in relation to sequence tagged sites mapped to the Langer-Giedion chromosomal region on somatic cell hybrids. The minimal region of overlap of Langer-Giedion syndrome deletions, previously identified by analysis of 15 patients, was placed on the map by analysis of 2 patients whose deletions define the endpoints. The chromosome 8 breakpoint of a balanced t(8;9)(q24.11;q33.3) translocation from a patient with trichorhinophalangeal syndrome (TRPS I) was found to be located just within the proximal end of the minimal deletion region. A deletion of 8q24.11-q24.3 in a patient with multiple exostoses was found to overlap the distal end of the LGS deletion region, indicating that the EXT1 gene is distal to the TRPS1 gene and supporting the hypothesis that Langer-Giedion syndrome is due to loss of functional copies of both the TRPS1 and the EXT1 genes. Show less
no PDF DOI: 10.1006/geno.1995.1218
EXT1
W Wuyts, S Ramlakhan, W Van Hul +7 more · 1995 · American journal of human genetics · added 2026-04-24
Hereditary multiple exostoses (EXT) is an autosomal dominant skeletal disorder characterized by the formation of multiple exostoses on the long bones. EXT is genetically heterogeneous, with at least t Show more
Hereditary multiple exostoses (EXT) is an autosomal dominant skeletal disorder characterized by the formation of multiple exostoses on the long bones. EXT is genetically heterogeneous, with at least three loci involved: one (EXT1) in the Langer-Giedion region on 8q23-q24, a second (EXT2) in the pericentromeric region of chromosome 11, and a third (EXT3) on chromosome 19p. In this study, linkage analysis in seven extended EXT families, all linked to the EXT2 locus, refined the localization of the EXT2 gene to a 3-cM region flanked by D11S1355 and D11S1361/D11S554. This implies that the EXT2 gene is located at the short arm of chromosome 11, in band 11p11-p12. The refined localization of EXT2 excludes a number of putative candidate genes located in the pericentromeric region of chromosome 11 and facilitates the process of isolating the EXT2 gene. Show less
no PDF
EXT1
K L Dry, M A Aldred, A J Edgar +7 more · 1995 · Human molecular genetics · Oxford University Press · added 2026-04-24
A novel gene encoding a 2.2 kilobase transcript has been isolated from the Xp21.1 region of the human X chromosome by exon amplification. The gene, called EXT1, spans 80 kilobases and contains 12 exon Show more
A novel gene encoding a 2.2 kilobase transcript has been isolated from the Xp21.1 region of the human X chromosome by exon amplification. The gene, called EXT1, spans 80 kilobases and contains 12 exons, at least two of which are alternatively spliced and have predicted products of 464 and 471 amino acids respectively. Conceptual translation of the open reading frames shows one product with a 30 amino acid signal peptide, which is absent from the alternative transcript, followed by three complement control protein domains, a hydrophobic region with a possible role in membrane anchorage and short 17 amino acid putative cytoplasmic carboxyl terminus. An alternative first exon contains a 39 amino acid open reading frame which is rich in serine and threonine residues and contains a potential chondroitin/dermatan sulphate attachment site. Northern analysis showed ETX1 expression within the retina and heart with lower levels in several other tissues. Since ETX1 lies within the region thought to contain the x-linked retinitis pigmentosa (xIRP) gene, RP3, it was screened for mutation within a set of 45 xIRP patients using single strand conformation analysis and/or chemical cleavage of mismatch using reverse transcription/polymerase chain reaction amplification of polyA+RNA from blood cells. Three low frequently variants (17-23Ldel, P225S, S413F) were found in both patients and controls; one of which (P225S) was found in four of 45 unrelated patient chromosomes and one of 178 control chromosomes (p <0.001). The allelic association between P225S and xIRP alleles suggests a common ancestral chromosome bearing the P225S variant and an RP3 mutation at a neighbouring locus. Show less
no PDF DOI: 10.1093/hmg/4.12.2347
EXT1